Kevin Lind, Longboard Pharmaceuticals CEO
January 2, 2024 01:46 PM ESTUpdated 02:06 PM
R&D
Pharma

Long­board stock soars on heels of pos­i­tive topline da­ta for seizure med­ica­tion

Lia DeGroot

Long­board Phar­ma­ceu­ti­cals’ stock $LBPH sky­rock­et­ed by more than 200% Tues­day af­ter the com­pa­ny re­leased topline da­ta from its study for an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Bay­er says elin­zane­tant quelled hot flash­es in women un­der­go­ing can­cer treat­ment

A service from the Financial Times